F-star appoints Neil Brewis as chief scientific officer

F-star, a biotech company originally founded in Vienna, Austria, but now mainly based in the UK, has appointed Neil Brewis as chief scientific officer.

Dr Brewis joins from UK pharma major GlaxoSmithKline (LSE: GSK) where he was vice president, head of biopharma research. There he led a global team of 300 scientists on advancing monoclonal antibodies, antibody fragments and protein therapeutics from target validation to clinical development.

John Haurum, chief executive officer of F-star, said: “We are very pleased to welcome Neil to our team. His significant track record and expertise in applying antibody technologies to discover and develop clinical products will further enable us to move our portfolio of immuno-oncology compounds into the clinic. This appointment strengthens our experienced management team and supports F-star’s strategy to lead the bispecific antibody space in immuno-oncology. It also demonstrates the unmatched attraction of Cambridge as the foremost biotech cluster in Europe, serving as a key hub for biopharmaceutical companies and academic excellence within antibody drug discovery and development.”